BioMarin Pharmaceutical heads into its May 4 Q1 earnings report with short sellers at their most committed in months — a notable shift for a stock where positioning had been relatively relaxed for much of the first quarter.
The dominant story this week is the sharp rebuild in short interest. SI climbed from 4.4% of free float in mid-April to 5.25% — a 13% week-on-week increase and 22% higher than a month ago. The jump was sudden and concentrated: nearly 1.2 million shares of short exposure arrived between April 22 and April 24 alone, lifting the total to around 10.1 million shares. Before that date, the position had been rangebound between 4.3% and 4.7% since early March. The acceleration marks a clear change of view heading into the print.
The borrow market, however, is not alarmed. Cost to borrow runs at a modest 0.38% — up roughly 16% over the week but still barely above zero in absolute terms, reflecting easy access to stock to lend. Availability remains loose: the lending pool is far from stretched, with availability well above stress levels, and the ORTEX short score sits at 41.9, broadly neutral and well shy of territory that would signal a squeeze setup. Options traders tell the opposite story to the short rebuilders. The put/call ratio has dropped to 0.38 — the lowest reading of the past 52 weeks, sitting 1.3 standard deviations below its 20-day mean of 0.47. That means options buyers are heavily skewed toward calls, treating the upcoming earnings not as a risk event but as a potential catalyst to the upside. The divergence between a rebuilding short book and a call-dominated options market is the central tension in BMRN positioning right now.
The Street remains firmly in the bull camp, though with a touch of caution baked in since February's results. Analyst consensus reads as buy, with five outperform ratings and a mean price target of $90.17 — roughly 69% above Monday's close of $53.30. That gap is wide enough to warrant some scrutiny of its own. The most recent notable move came in early March, when B of A Securities maintained its Buy but trimmed the target from $97 to $85, while Barclays moved the other way, raising its Overweight target from $80 to $105. The overall directional message from the Street is bullish, but the February earnings print clearly triggered a round of target resets: Guggenheim cut from $106 to $86, Oppenheimer trimmed to $95 from $98, and HC Wainwright held its lone Neutral at $55. Factor scores support the constructive view on fundamentals: forward EPS growth ranks in the 95th percentile, EPS momentum scores 72 and 74 over 30 and 90 days respectively, and the analyst recommendation differential scores in the 91st percentile — suggesting the Street is materially more positive on BMRN than on the average stock in its universe.
The bull case centres on BioMarin's rare-disease franchise generating $3.3–3.4 billion in 2026 revenue with a clear path toward $4 billion by 2027 and operating margins above 40%. Bears counter that upcoming pipeline data on BMN-333 in skeletal disorders faces a tough competitive bar, with competing therapies already in market. The February Q4 print — which sent the stock down 2.3% on the day and 6.8% over the following week — has kept that competitive anxiety alive. Peers have had a mixed week: CYTK fell 7.8%, CTOR dropped 3.7%, and IONS declined 4.0%, while KNSA surged 26.9% on its own specific catalyst. The group-wide weakness adds context to BMRN's 2.4% week-on-week decline — this isn't idiosyncratic selling ahead of the print, but sector pressure hasn't helped.
Institutional ownership is concentrated at the top: BlackRock and Vanguard each hold roughly 9.4% and 9.4% of shares respectively, and Dodge & Cox sits at 7.5%. Vanguard added 716,000 shares as of end-March, and Dimensional added just over 1 million — both modest increments rather than conviction-level repositioning. Insider activity through mid-March was uniformly selling across C-suite and senior management, including the CEO, CFO, and CTO, at prices between $56 and $58.51 — above the current level of $53.30. The trades were small in absolute terms and carried the lowest significance score, consistent with scheduled programme selling rather than directional signals.
The Q1 print on May 4 is the next hard data point. With shorts rebuilt, options tilted call-heavy, and the Street 69% above the current price on its mean target, the debate will centre on whether revenue guidance for 2026 confirms or challenges the $3.3–3.4 billion range — and whether pipeline commentary on BMN-333 addresses the competitive pressure that has weighed on the stock since February.
See the live data behind this article on ORTEX.
Open BMRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
